The global market for Ustekinumab Injection was valued at US$ 15021 million in the year 2024 and is projected to reach a revised size of US$ 22732 million by 2031, growing at a CAGR of 6.1% during the forecast period.

Ustekinumab Injection Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Ustekinumab Injection competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Ustekinumab Injection is a formulation containing ustekinumab as the active ingredient, which is a fully human IgG1κ monoclonal antibody. It works by specifically binding to the p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby blocking their interaction with receptors and inhibiting the activation of associated inflammatory signaling pathways. This injectable medication is commonly indicated for the treatment of immune-mediated diseases such as moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. In 2024, the global production volume of ustekinumab injection was 3.9 million syringes, with an average price of USD 3,852 per syringe.

Market Overview

The ustekinumab market has maintained steady growth in recent years, driven by increasing demand from patients for effective and low-frequency dosing regimens. Growth is observed not only in established indications but also supported by clinical expansion into new therapeutic areas and the gradual introduction of biosimilars, contributing to overall market development.

Regional Market Landscape

Globally, the United States accounts for 50% of the market, Europe for 20%, Asia for 15%, and other regions for 15%, reflecting a market structure centered on North America and Europe, while the Asian market is rapidly penetrating and gradually forming a strong growth momentum.

Key Manufacturers and Industry Competition

The originator maintains a dominant position worldwide, but competition has intensified with the expiration of patents and the entry of biosimilars. Multiple international and regional companies are competing in the development, production, and commercialization of both originator and biosimilar products, while collaboration and licensing strategies are used to optimize market positioning.

Technological Trends and Innovation Directions

Technological innovation is primarily focused on high-concentration formulations and convenient administration methods, alongside optimization of biosimilars and research into combination therapy strategies. These innovations improve treatment adherence and provide technical support for expansion into new indications, facilitating broader clinical adoption.

Policy and Industry Development Drivers

Supportive healthcare policies and accelerated biosimilar approvals are key drivers of market growth, alongside increasing patient acceptance of innovative therapies. Regulatory optimization and industry guidance together promote the market’s standardization and scale expansion.

Future Outlook

Looking ahead, the ustekinumab market is expected to maintain steady growth amid intensified competition, with potential increases in market concentration. Expansion into new indications and personalized therapies will be major growth drivers, while technological innovation, regional penetration, and policy support will collectively shape the future market landscape.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Ustekinumab Injection, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ustekinumab Injection.

The Ustekinumab Injection market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Ustekinumab Injection market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Ustekinumab Injection manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Ustekinumab Injection Market Report

Report Metric	Details
Report Name	Ustekinumab Injection Market
Accounted market size in year	US$ 15021 million
Forecasted market size in 2031	US$ 22732 million
CAGR	6.1%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Original Drug Biosimilars
Segment by Application	Plaque Psoriasis Psoriatic Arthritis Crohn’s Disease Ulcerative Colitis Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Meiji, Johnson & Johnson, Alvotech, Fuji Pharma, Mitsubishi, Tanabe, Stada, EPIRUS, BioPharma, Formycon, NeuClone, Amgen, Sandoz, Biocon Biologics, Huadong Medicine
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Ustekinumab Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Ustekinumab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Ustekinumab Injection Market growing?

Ans: The Ustekinumab Injection Market witnessing a CAGR of 6.1% during the forecast period 2025-2031.

What is the Ustekinumab Injection Market size in 2031?

Ans: The Ustekinumab Injection Market size in 2031 will be US$ 22732 million.

What is the Ustekinumab Injection Market share by region?

Ans: Regional Market Landscape Globally, the United States accounts for 50% of the market, Europe for 20%, Asia for 15%, and other regions for 15%, reflecting a market structure centered on North America and Europe, while the Asian market is rapidly penetrating and gradually forming a strong growth momentum.

Who are the main players in the Ustekinumab Injection Market report?

Ans: The main players in the Ustekinumab Injection Market are Meiji, Johnson & Johnson, Alvotech, Fuji Pharma, Mitsubishi, Tanabe, Stada, EPIRUS, BioPharma, Formycon, NeuClone, Amgen, Sandoz, Biocon Biologics, Huadong Medicine

What are the Application segmentation covered in the Ustekinumab Injection Market report?

Ans: The Applications covered in the Ustekinumab Injection Market report are Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Others

What are the Type segmentation covered in the Ustekinumab Injection Market report?

Ans: The Types covered in the Ustekinumab Injection Market report are Original Drug, Biosimilars

1 Ustekinumab Injection Market Overview

1.1 Product Definition

1.2 Ustekinumab Injection by Type

1.2.1 Global Ustekinumab Injection Market Value Comparison by Type (2024 VS 2031)

1.2.2 Original Drug

1.2.3 Biosimilars

1.3 Ustekinumab Injection by Application

1.3.1 Global Ustekinumab Injection Market Value by Application (2024 VS 2031)

1.3.2 Plaque Psoriasis

1.3.3 Psoriatic Arthritis

1.3.4 Crohn’s Disease

1.3.5 Ulcerative Colitis

1.3.6 Others

1.4 Global Ustekinumab Injection Market Size Estimates and Forecasts

1.4.1 Global Ustekinumab Injection Revenue 2020-2031

1.4.2 Global Ustekinumab Injection Sales 2020-2031

1.4.3 Global Ustekinumab Injection Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Ustekinumab Injection Market Competition by Manufacturers

2.1 Global Ustekinumab Injection Sales Market Share by Manufacturers (2020-2025)

2.2 Global Ustekinumab Injection Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Ustekinumab Injection Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Ustekinumab Injection, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Ustekinumab Injection, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Ustekinumab Injection, Product Type & Application

2.7 Global Key Manufacturers of Ustekinumab Injection, Date of Enter into This Industry

2.8 Global Ustekinumab Injection Market Competitive Situation and Trends

2.8.1 Global Ustekinumab Injection Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Ustekinumab Injection Players Market Share by Revenue

2.8.3 Global Ustekinumab Injection Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Ustekinumab Injection Market Scenario by Region

3.1 Global Ustekinumab Injection Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Ustekinumab Injection Sales by Region: 2020-2031

3.2.1 Global Ustekinumab Injection Sales by Region: 2020-2025

3.2.2 Global Ustekinumab Injection Sales by Region: 2026-2031

3.3 Global Ustekinumab Injection Revenue by Region: 2020-2031

3.3.1 Global Ustekinumab Injection Revenue by Region: 2020-2025

3.3.2 Global Ustekinumab Injection Revenue by Region: 2026-2031

3.4 North America Ustekinumab Injection Market Facts & Figures by Country

3.4.1 North America Ustekinumab Injection Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Ustekinumab Injection Sales by Country (2020-2031)

3.4.3 North America Ustekinumab Injection Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Ustekinumab Injection Market Facts & Figures by Country

3.5.1 Europe Ustekinumab Injection Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Ustekinumab Injection Sales by Country (2020-2031)

3.5.3 Europe Ustekinumab Injection Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Ustekinumab Injection Market Facts & Figures by Region

3.6.1 Asia Pacific Ustekinumab Injection Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Ustekinumab Injection Sales by Region (2020-2031)

3.6.3 Asia Pacific Ustekinumab Injection Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Ustekinumab Injection Market Facts & Figures by Country

3.7.1 Latin America Ustekinumab Injection Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Ustekinumab Injection Sales by Country (2020-2031)

3.7.3 Latin America Ustekinumab Injection Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Ustekinumab Injection Market Facts & Figures by Country

3.8.1 Middle East and Africa Ustekinumab Injection Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Ustekinumab Injection Sales by Country (2020-2031)

3.8.3 Middle East and Africa Ustekinumab Injection Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Ustekinumab Injection Sales by Type (2020-2031)

4.1.1 Global Ustekinumab Injection Sales by Type (2020-2025)

4.1.2 Global Ustekinumab Injection Sales by Type (2026-2031)

4.1.3 Global Ustekinumab Injection Sales Market Share by Type (2020-2031)

4.2 Global Ustekinumab Injection Revenue by Type (2020-2031)

4.2.1 Global Ustekinumab Injection Revenue by Type (2020-2025)

4.2.2 Global Ustekinumab Injection Revenue by Type (2026-2031)

4.2.3 Global Ustekinumab Injection Revenue Market Share by Type (2020-2031)

4.3 Global Ustekinumab Injection Price by Type (2020-2031)

5 Segment by Application

5.1 Global Ustekinumab Injection Sales by Application (2020-2031)

5.1.1 Global Ustekinumab Injection Sales by Application (2020-2025)

5.1.2 Global Ustekinumab Injection Sales by Application (2026-2031)

5.1.3 Global Ustekinumab Injection Sales Market Share by Application (2020-2031)

5.2 Global Ustekinumab Injection Revenue by Application (2020-2031)

5.2.1 Global Ustekinumab Injection Revenue by Application (2020-2025)

5.2.2 Global Ustekinumab Injection Revenue by Application (2026-2031)

5.2.3 Global Ustekinumab Injection Revenue Market Share by Application (2020-2031)

5.3 Global Ustekinumab Injection Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Meiji

6.1.1 Meiji Company Information

6.1.2 Meiji Description and Business Overview

6.1.3 Meiji Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Meiji Ustekinumab Injection Product Portfolio

6.1.5 Meiji Recent Developments/Updates

6.2 Johnson & Johnson

6.2.1 Johnson & Johnson Company Information

6.2.2 Johnson & Johnson Description and Business Overview

6.2.3 Johnson & Johnson Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Johnson & Johnson Ustekinumab Injection Product Portfolio

6.2.5 Johnson & Johnson Recent Developments/Updates

6.3 Alvotech

6.3.1 Alvotech Company Information

6.3.2 Alvotech Description and Business Overview

6.3.3 Alvotech Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Alvotech Ustekinumab Injection Product Portfolio

6.3.5 Alvotech Recent Developments/Updates

6.4 Fuji Pharma

6.4.1 Fuji Pharma Company Information

6.4.2 Fuji Pharma Description and Business Overview

6.4.3 Fuji Pharma Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Fuji Pharma Ustekinumab Injection Product Portfolio

6.4.5 Fuji Pharma Recent Developments/Updates

6.5 Mitsubishi

6.5.1 Mitsubishi Company Information

6.5.2 Mitsubishi Description and Business Overview

6.5.3 Mitsubishi Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Mitsubishi Ustekinumab Injection Product Portfolio

6.5.5 Mitsubishi Recent Developments/Updates

6.6 Tanabe

6.6.1 Tanabe Company Information

6.6.2 Tanabe Description and Business Overview

6.6.3 Tanabe Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Tanabe Ustekinumab Injection Product Portfolio

6.6.5 Tanabe Recent Developments/Updates

6.7 Stada

6.7.1 Stada Company Information

6.7.2 Stada Description and Business Overview

6.7.3 Stada Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Stada Ustekinumab Injection Product Portfolio

6.7.5 Stada Recent Developments/Updates

6.8 EPIRUS

6.8.1 EPIRUS Company Information

6.8.2 EPIRUS Description and Business Overview

6.8.3 EPIRUS Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.8.4 EPIRUS Ustekinumab Injection Product Portfolio

6.8.5 EPIRUS Recent Developments/Updates

6.9 BioPharma

6.9.1 BioPharma Company Information

6.9.2 BioPharma Description and Business Overview

6.9.3 BioPharma Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.9.4 BioPharma Ustekinumab Injection Product Portfolio

6.9.5 BioPharma Recent Developments/Updates

6.10 Formycon

6.10.1 Formycon Company Information

6.10.2 Formycon Description and Business Overview

6.10.3 Formycon Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Formycon Ustekinumab Injection Product Portfolio

6.10.5 Formycon Recent Developments/Updates

6.11 NeuClone

6.11.1 NeuClone Company Information

6.11.2 NeuClone Description and Business Overview

6.11.3 NeuClone Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.11.4 NeuClone Ustekinumab Injection Product Portfolio

6.11.5 NeuClone Recent Developments/Updates

6.12 Amgen

6.12.1 Amgen Company Information

6.12.2 Amgen Description and Business Overview

6.12.3 Amgen Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Amgen Ustekinumab Injection Product Portfolio

6.12.5 Amgen Recent Developments/Updates

6.13 Sandoz

6.13.1 Sandoz Company Information

6.13.2 Sandoz Description and Business Overview

6.13.3 Sandoz Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Sandoz Ustekinumab Injection Product Portfolio

6.13.5 Sandoz Recent Developments/Updates

6.14 Biocon Biologics

6.14.1 Biocon Biologics Company Information

6.14.2 Biocon Biologics Description and Business Overview

6.14.3 Biocon Biologics Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.14.4 Biocon Biologics Ustekinumab Injection Product Portfolio

6.14.5 Biocon Biologics Recent Developments/Updates

6.15 Huadong Medicine

6.15.1 Huadong Medicine Company Information

6.15.2 Huadong Medicine Description and Business Overview

6.15.3 Huadong Medicine Ustekinumab Injection Sales, Revenue and Gross Margin (2020-2025)

6.15.4 Huadong Medicine Ustekinumab Injection Product Portfolio

6.15.5 Huadong Medicine Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Ustekinumab Injection Industry Chain Analysis

7.2 Ustekinumab Injection Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Ustekinumab Injection Production Mode & Process Analysis

7.4 Ustekinumab Injection Sales and Marketing

7.4.1 Ustekinumab Injection Sales Channels

7.4.2 Ustekinumab Injection Distributors

7.5 Ustekinumab Injection Customer Analysis

8 Ustekinumab Injection Market Dynamics

8.1 Ustekinumab Injection Industry Trends

8.2 Ustekinumab Injection Market Drivers

8.3 Ustekinumab Injection Market Challenges

8.4 Ustekinumab Injection Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Ustekinumab Injection Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Ustekinumab Injection Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Ustekinumab Injection Market Competitive Situation by Manufacturers in 2024

Table 4. Global Ustekinumab Injection Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Ustekinumab Injection Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Ustekinumab Injection Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Ustekinumab Injection Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Ustekinumab Injection Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Ustekinumab Injection, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Ustekinumab Injection, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Ustekinumab Injection, Product Type & Application

Table 12. Global Key Manufacturers of Ustekinumab Injection, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Ustekinumab Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ustekinumab Injection as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Ustekinumab Injection Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Ustekinumab Injection Sales by Region (2020-2025) & (K Units)

Table 18. Global Ustekinumab Injection Sales Market Share by Region (2020-2025)

Table 19. Global Ustekinumab Injection Sales by Region (2026-2031) & (K Units)

Table 20. Global Ustekinumab Injection Sales Market Share by Region (2026-2031)

Table 21. Global Ustekinumab Injection Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Ustekinumab Injection Revenue Market Share by Region (2020-2025)

Table 23. Global Ustekinumab Injection Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Ustekinumab Injection Revenue Market Share by Region (2026-2031)

Table 25. North America Ustekinumab Injection Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Ustekinumab Injection Sales by Country (2020-2025) & (K Units)

Table 27. North America Ustekinumab Injection Sales by Country (2026-2031) & (K Units)

Table 28. North America Ustekinumab Injection Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Ustekinumab Injection Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Ustekinumab Injection Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Ustekinumab Injection Sales by Country (2020-2025) & (K Units)

Table 32. Europe Ustekinumab Injection Sales by Country (2026-2031) & (K Units)

Table 33. Europe Ustekinumab Injection Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Ustekinumab Injection Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Ustekinumab Injection Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Ustekinumab Injection Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Ustekinumab Injection Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Ustekinumab Injection Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Ustekinumab Injection Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Ustekinumab Injection Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Ustekinumab Injection Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Ustekinumab Injection Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Ustekinumab Injection Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Ustekinumab Injection Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Ustekinumab Injection Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Ustekinumab Injection Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Ustekinumab Injection Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Ustekinumab Injection Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Ustekinumab Injection Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Ustekinumab Injection Sales (K Units) by Type (2020-2025)

Table 51. Global Ustekinumab Injection Sales (K Units) by Type (2026-2031)

Table 52. Global Ustekinumab Injection Sales Market Share by Type (2020-2025)

Table 53. Global Ustekinumab Injection Sales Market Share by Type (2026-2031)

Table 54. Global Ustekinumab Injection Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Ustekinumab Injection Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Ustekinumab Injection Revenue Market Share by Type (2020-2025)

Table 57. Global Ustekinumab Injection Revenue Market Share by Type (2026-2031)

Table 58. Global Ustekinumab Injection Price (US$/Unit) by Type (2020-2025)

Table 59. Global Ustekinumab Injection Price (US$/Unit) by Type (2026-2031)

Table 60. Global Ustekinumab Injection Sales (K Units) by Application (2020-2025)

Table 61. Global Ustekinumab Injection Sales (K Units) by Application (2026-2031)

Table 62. Global Ustekinumab Injection Sales Market Share by Application (2020-2025)

Table 63. Global Ustekinumab Injection Sales Market Share by Application (2026-2031)

Table 64. Global Ustekinumab Injection Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Ustekinumab Injection Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Ustekinumab Injection Revenue Market Share by Application (2020-2025)

Table 67. Global Ustekinumab Injection Revenue Market Share by Application (2026-2031)

Table 68. Global Ustekinumab Injection Price (US$/Unit) by Application (2020-2025)

Table 69. Global Ustekinumab Injection Price (US$/Unit) by Application (2026-2031)

Table 70. Meiji Company Information

Table 71. Meiji Description and Business Overview

Table 72. Meiji Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Meiji Ustekinumab Injection Product

Table 74. Meiji Recent Developments/Updates

Table 75. Johnson & Johnson Company Information

Table 76. Johnson & Johnson Description and Business Overview

Table 77. Johnson & Johnson Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Johnson & Johnson Ustekinumab Injection Product

Table 79. Johnson & Johnson Recent Developments/Updates

Table 80. Alvotech Company Information

Table 81. Alvotech Description and Business Overview

Table 82. Alvotech Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Alvotech Ustekinumab Injection Product

Table 84. Alvotech Recent Developments/Updates

Table 85. Fuji Pharma Company Information

Table 86. Fuji Pharma Description and Business Overview

Table 87. Fuji Pharma Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Fuji Pharma Ustekinumab Injection Product

Table 89. Fuji Pharma Recent Developments/Updates

Table 90. Mitsubishi Company Information

Table 91. Mitsubishi Description and Business Overview

Table 92. Mitsubishi Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Mitsubishi Ustekinumab Injection Product

Table 94. Mitsubishi Recent Developments/Updates

Table 95. Tanabe Company Information

Table 96. Tanabe Description and Business Overview

Table 97. Tanabe Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Tanabe Ustekinumab Injection Product

Table 99. Tanabe Recent Developments/Updates

Table 100. Stada Company Information

Table 101. Stada Description and Business Overview

Table 102. Stada Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Stada Ustekinumab Injection Product

Table 104. Stada Recent Developments/Updates

Table 105. EPIRUS Company Information

Table 106. EPIRUS Description and Business Overview

Table 107. EPIRUS Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. EPIRUS Ustekinumab Injection Product

Table 109. EPIRUS Recent Developments/Updates

Table 110. BioPharma Company Information

Table 111. BioPharma Description and Business Overview

Table 112. BioPharma Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. BioPharma Ustekinumab Injection Product

Table 114. BioPharma Recent Developments/Updates

Table 115. Formycon Company Information

Table 116. Formycon Description and Business Overview

Table 117. Formycon Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. Formycon Ustekinumab Injection Product

Table 119. Formycon Recent Developments/Updates

Table 120. NeuClone Company Information

Table 121. NeuClone Description and Business Overview

Table 122. NeuClone Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 123. NeuClone Ustekinumab Injection Product

Table 124. NeuClone Recent Developments/Updates

Table 125. Amgen Company Information

Table 126. Amgen Description and Business Overview

Table 127. Amgen Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 128. Amgen Ustekinumab Injection Product

Table 129. Amgen Recent Developments/Updates

Table 130. Sandoz Company Information

Table 131. Sandoz Description and Business Overview

Table 132. Sandoz Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 133. Sandoz Ustekinumab Injection Product

Table 134. Sandoz Recent Developments/Updates

Table 135. Biocon Biologics Company Information

Table 136. Biocon Biologics Description and Business Overview

Table 137. Biocon Biologics Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 138. Biocon Biologics Ustekinumab Injection Product

Table 139. Biocon Biologics Recent Developments/Updates

Table 140. Huadong Medicine Company Information

Table 141. Huadong Medicine Description and Business Overview

Table 142. Huadong Medicine Ustekinumab Injection Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 143. Huadong Medicine Ustekinumab Injection Product

Table 144. Huadong Medicine Recent Developments/Updates

Table 145. Key Raw Materials Lists

Table 146. Raw Materials Key Suppliers Lists

Table 147. Ustekinumab Injection Distributors List

Table 148. Ustekinumab Injection Customers List

Table 149. Ustekinumab Injection Market Trends

Table 150. Ustekinumab Injection Market Drivers

Table 151. Ustekinumab Injection Market Challenges

Table 152. Ustekinumab Injection Market Restraints

Table 153. Research Programs/Design for This Report

Table 154. Key Data Information from Secondary Sources

Table 155. Key Data Information from Primary Sources

Table 156. Authors List of This Report

List of Figures

Figure 1. Product Picture of Ustekinumab Injection

Figure 2. Global Ustekinumab Injection Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Ustekinumab Injection Market Share by Type: 2024 & 2031

Figure 4. Original Drug Product Picture

Figure 5. Biosimilars Product Picture

Figure 6. Global Ustekinumab Injection Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Ustekinumab Injection Market Share by Application: 2024 & 2031

Figure 8. Plaque Psoriasis

Figure 9. Psoriatic Arthritis

Figure 10. Crohn’s Disease

Figure 11. Ulcerative Colitis

Figure 12. Others

Figure 13. Global Ustekinumab Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Ustekinumab Injection Market Size (2020-2031) & (US$ Million)

Figure 15. Global Ustekinumab Injection Sales (2020-2031) & (K Units)

Figure 16. Global Ustekinumab Injection Average Price (US$/Unit) & (2020-2031)

Figure 17. Ustekinumab Injection Report Years Considered

Figure 18. Ustekinumab Injection Sales Share by Manufacturers in 2024

Figure 19. Global Ustekinumab Injection Revenue Share by Manufacturers in 2024

Figure 20. Global 5 and 10 Largest Ustekinumab Injection Players: Market Share by Revenue in Ustekinumab Injection in 2024

Figure 21. Ustekinumab Injection Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 22. Global Ustekinumab Injection Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 23. North America Ustekinumab Injection Sales Market Share by Country (2020-2031)

Figure 24. North America Ustekinumab Injection Revenue Market Share by Country (2020-2031)

Figure 25. United States Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Canada Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Europe Ustekinumab Injection Sales Market Share by Country (2020-2031)

Figure 28. Europe Ustekinumab Injection Revenue Market Share by Country (2020-2031)

Figure 29. Germany Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. France Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. U.K. Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Italy Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Russia Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Asia Pacific Ustekinumab Injection Sales Market Share by Region (2020-2031)

Figure 35. Asia Pacific Ustekinumab Injection Revenue Market Share by Region (2020-2031)

Figure 36. China Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Japan Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. South Korea Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. India Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Australia Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. China Taiwan Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Southeast Asia Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Latin America Ustekinumab Injection Sales Market Share by Country (2020-2031)

Figure 44. Latin America Ustekinumab Injection Revenue Market Share by Country (2020-2031)

Figure 45. Mexico Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Brazil Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Argentina Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Middle East and Africa Ustekinumab Injection Sales Market Share by Country (2020-2031)

Figure 49. Middle East and Africa Ustekinumab Injection Revenue Market Share by Country (2020-2031)

Figure 50. Turkey Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Saudi Arabia Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. UAE Ustekinumab Injection Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Global Sales Market Share of Ustekinumab Injection by Type (2020-2031)

Figure 54. Global Revenue Market Share of Ustekinumab Injection by Type (2020-2031)

Figure 55. Global Ustekinumab Injection Price (US$/Unit) by Type (2020-2031)

Figure 56. Global Sales Market Share of Ustekinumab Injection by Application (2020-2031)

Figure 57. Global Revenue Market Share of Ustekinumab Injection by Application (2020-2031)

Figure 58. Global Ustekinumab Injection Price (US$/Unit) by Application (2020-2031)

Figure 59. Ustekinumab Injection Value Chain

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions